Send the following on WhatsApp
Continue to Chathttps://es.marketscreener.com/cotizacion/accion/TAKEDA-PHARMACEUTICAL-COM-6491073/noticia/Takeda-adquiere-la-licencia-mundial-exclusiva-excepto-en-China-de-fruquintinib-de-HUTCHMED-un-inh-42792921/?utm_source=whatsapp&utm_medium=social&utm_campaign=share